fusion glp 1 GLP-ONE + Receptor Activator Stability engineering of GLP-1 analogue

Adv Exp Med Biol 272:175181

Studies show that the combined use of Y1 receptor agonists and GLP-1 receptor agonists (GLP-1RA) can induce -cells into a rest state in an obesity-driven diabetes model and promote the recovery of -cell function ( Regulating the proliferation of intestinal L cells and PYY secretion can endogenously increase PYY levels, avoiding the side effects of exogenous administration

Since then, the evolution of GLP-1 receptor agonists has progressed from initial short-duration agents like exenatide, to intermediate-duration formulations such as liraglutide, and further to advanced long-acting options including dulaglutide and semaglutide (The two products received approval for marketing in the U.S

Semaglutide has the longer real-world safety track record and typically costs less